- Home
- SNAL vs STTK Comparison
SNAL vs STTK Comparison
Compare SNAL & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNAL
- STTK
- Stock Information
- Founded
- SNAL 2000
- STTK 2016
- Country
- SNAL United States
- STTK United States
- Employees
- SNAL N/A
- STTK N/A
- Industry
- SNAL Computer Software: Prepackaged Software
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- SNAL Technology
- STTK Health Care
- Exchange
- SNAL Nasdaq
- STTK Nasdaq
- Market Cap
- SNAL 40.0M
- STTK 37.6M
- IPO Year
- SNAL 2022
- STTK 2020
- Fundamental
- Price
- SNAL $1.35
- STTK $0.96
- Analyst Decision
- SNAL
- STTK Hold
- Analyst Count
- SNAL 0
- STTK 4
- Target Price
- SNAL N/A
- STTK $3.00
- AVG Volume (30 Days)
- SNAL 70.7K
- STTK 117.7K
- Earning Date
- SNAL 08-12-2025
- STTK 07-31-2025
- Dividend Yield
- SNAL N/A
- STTK N/A
- EPS Growth
- SNAL N/A
- STTK N/A
- EPS
- SNAL 0.04
- STTK N/A
- Revenue
- SNAL $90,462,190.00
- STTK $4,606,000.00
- Revenue This Year
- SNAL $24.50
- STTK N/A
- Revenue Next Year
- SNAL $20.27
- STTK N/A
- P/E Ratio
- SNAL $35.90
- STTK N/A
- Revenue Growth
- SNAL 46.95
- STTK 69.65
- 52 Week Low
- SNAL $0.52
- STTK $0.69
- 52 Week High
- SNAL $3.42
- STTK $4.99
- Technical
- Relative Strength Index (RSI)
- SNAL 61.32
- STTK 44.24
- Support Level
- SNAL $1.10
- STTK $0.95
- Resistance Level
- SNAL $1.65
- STTK $1.24
- Average True Range (ATR)
- SNAL 0.18
- STTK 0.08
- MACD
- SNAL 0.04
- STTK -0.02
- Stochastic Oscillator
- SNAL 50.00
- STTK 5.05
About SNAL Snail Inc.
Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.